BioCentury
ARTICLE | Clinical News

Hemolink purified hemoglobin blood substitute: Began recruiting 36 volunteers for a Phase I Canadian trial using escalating doses of less than 50 grams

February 21, 1995 8:00 AM UTC

Hemosol Inc. (HML), Etobicoke, Ontario Product: Hemolink purified hemoglobin blood substitute Indication: Blood loss, tumor oxygenation for cancer therapy, coronary angioplasty Status: Began recruitin...